Xorte logo

News Markets Groups

USA | Europe | Asia | World| Stocks | Commodities



Add a new RSS channel

 
 


Keywords

2023-05-26 02:15:41| Engadget

Turns out Elon Musk's FDA prediction was only off by about a month. After reportedly denying the company's overtures in March, the FDA approved Neuralink's application to begin human trials of its prototype Link brain-computer interface (BCI) on Thursday. Founded in 2016, Neuralink aims to commercialize BCIs in wide-ranging medical and therapeutic applications from stroke and spinal cord injury (SCI) rehabilitation, to neural prosthetic controls, to the capacity "to rewind memories or download them into robots," Neuralink CEO Elon Musk promised in 2020. BCIs essentially translate the analog electrical impulses of your brain (monitoring it using hair-thin electrodes delicately threaded into that grey matter) into the digital 1's and 0's that computers understand. Since that BCI needs to be surgically installed in a patient's noggin, the FDA which regulates such technologies requires that companies conduct rigorous safety testing before giving its approval for commercial use. In March, the FDA rejected Neuralink's application to begin human trials reportedly in part due to all the test animals that kept dying after having the prototype BCI implanted. According to internal documents acquired by Reuters in December, more than 1,500 animals had been killed in the development of the Neuralink BCI since 2018. The US Department of Agriculture's (USDA) Inspector General has since launched an investigation into those allegations.  The FDA's reticence was also born from concerns about the design and function of the interface when implanted in humans. "The agencys major safety concerns involved the devices lithium battery; the potential for the implants tiny wires to migrate to other areas of the brain; and questions over whether and how the device can be removed without damaging brain tissue," current and former Neuralink employees told Reuters in March.While Neuralink has obtained FDA approval to begin its study, the company is not yet seeking volunteers. This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people," Neuralink Tweeted on Thursday. "Recruitment is not yet open for our clinical trial."  This article originally appeared on Engadget at https://www.engadget.com/neuralink-receives-fda-clearance-to-begin-human-trials-of-its-brain-computer-interface-001504243.html?src=rss


Category: Marketing and Advertising

 

Latest from this category

01.12Renault and Maison Kayser celebrate French heritage with a baguette giveaway
28.11Florida buyers are first to close on a home using AI, saving thousands in realtor fees
27.11Decathlon asks folks to shoot them an invite this Black Friday  for sports, not shopping
26.11SMB Landing Page Optimization Trends
26.11How to Turn a Branded B2B Podcast Into a High-Impact Revenue Engine
26.11With its new course, MasterClass reframes cybersecurity as a must-have skill for consumers
25.11The Top Frustrations B2B Buyers Have With Vendors
25.11How US Professionals Are Building Their Personal Brands [Infographic]
Marketing and Advertising »

All news

02.12Asian stocks edge up, Japan bond auction in focus
02.12IPO Frenzy Continues: December to see nearly Rs 30,000 crore worth of public issues
02.12Is Aequs IPO a long-term bet or a wait-and-watch opportunity?
02.12Former counselor at Hartgrove Behavioral Health Hospital in Chicago charged with sexually assaulting 5 patients
02.12OBR head's resignation leaves potential landmines for Reeves
02.12Why time is running out for Germany's green hydrogen industry
02.12Share of term deposits paying above 7% falls sharply in Q2
02.12Sebi brass opposes public disclosure of financial details
More »
Privacy policy . Copyright . Contact form .